EA201791632A1 - Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат - Google Patents
Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоатInfo
- Publication number
- EA201791632A1 EA201791632A1 EA201791632A EA201791632A EA201791632A1 EA 201791632 A1 EA201791632 A1 EA 201791632A1 EA 201791632 A EA201791632 A EA 201791632A EA 201791632 A EA201791632 A EA 201791632A EA 201791632 A1 EA201791632 A1 EA 201791632A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dry powder
- dose
- fluticasone propionate
- user
- fluticason
- Prior art date
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
- 229960004017 salmeterol Drugs 0.000 title 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562105479P | 2015-01-20 | 2015-01-20 | |
| PCT/US2016/014072 WO2016118589A1 (en) | 2015-01-20 | 2016-01-20 | Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201791632A1 true EA201791632A1 (ru) | 2017-12-29 |
Family
ID=55443303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791632A EA201791632A1 (ru) | 2015-01-20 | 2016-01-20 | Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9415008B2 (enExample) |
| EP (1) | EP3247331A1 (enExample) |
| JP (1) | JP2018503687A (enExample) |
| KR (1) | KR20170103975A (enExample) |
| CN (1) | CN107530357A (enExample) |
| AR (1) | AR104771A1 (enExample) |
| AU (2) | AU2016209363B2 (enExample) |
| BR (1) | BR112017015353A2 (enExample) |
| CA (1) | CA2974125A1 (enExample) |
| CL (1) | CL2017001859A1 (enExample) |
| CO (1) | CO2017008395A2 (enExample) |
| EA (1) | EA201791632A1 (enExample) |
| HK (1) | HK1245125A1 (enExample) |
| IL (1) | IL253499A0 (enExample) |
| MA (1) | MA41378A (enExample) |
| MX (2) | MX383344B (enExample) |
| PE (1) | PE20171258A1 (enExample) |
| TW (1) | TW201628607A (enExample) |
| WO (1) | WO2016118589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160243320A1 (en) * | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| ES2884802T3 (es) * | 2016-11-18 | 2021-12-13 | Norton Waterford Ltd | Dispositivo de administración de fármacos con componentes electrónicos |
| CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
| CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN110064110A (zh) * | 2019-05-29 | 2019-07-30 | 上海理工大学 | 一种容积旋钮式干粉储存吸入装置 |
| GB2585206B (en) * | 2019-07-01 | 2021-08-11 | Merxin Ltd | Portable inhaler |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| AR028747A1 (es) | 2000-06-23 | 2003-05-21 | Norton Health Care Ltd | Desaglomerador para inhalador de polvo seco accionado por la respiracion, un inhalador de polvo seco y un metodo de desaglomeracion de polvo seco. |
| TWI224514B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Dose metering system for medicament inhaler |
| AR030516A1 (es) * | 2000-08-31 | 2003-08-20 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
| DK1337240T4 (en) * | 2000-11-30 | 2015-01-05 | Vectura Ltd | A process for the preparation of particles for use in a pharmaceutical composition |
| GB0124523D0 (en) | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| CN1694689A (zh) | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| TWI792140B (zh) * | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
| CN102573886A (zh) * | 2009-09-17 | 2012-07-11 | 相互制药公司 | 用抗病毒剂治疗哮喘的方法 |
| GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| PL2436414T3 (pl) * | 2010-05-18 | 2015-10-30 | Ivax Pharmaceuticals Ireland | Licznik dawek do inhalatorów i inhalator |
| WO2011145109A1 (en) | 2010-05-20 | 2011-11-24 | Sun Pharma Advanced Research Company Ltd., | Dry powder inhalation composition |
| KR20130140358A (ko) * | 2012-06-14 | 2013-12-24 | 한미약품 주식회사 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
| AU2014261539A1 (en) * | 2013-04-29 | 2015-12-10 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
| CN105358520B (zh) * | 2013-05-03 | 2017-05-03 | 陶氏环球技术有限责任公司 | 平衡限制反应的方法 |
| US20160243320A1 (en) | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| JP6653324B2 (ja) * | 2014-10-16 | 2020-02-26 | テバ ブランデッド ファーマシューティカル プロダクツ アール アンド ディー インコーポレイテッド | 乾燥粉末製剤 |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2016
- 2016-01-19 MA MA041378A patent/MA41378A/fr unknown
- 2016-01-20 EP EP16706919.4A patent/EP3247331A1/en not_active Withdrawn
- 2016-01-20 MX MX2017009122A patent/MX383344B/es unknown
- 2016-01-20 TW TW105101637A patent/TW201628607A/zh unknown
- 2016-01-20 JP JP2017556791A patent/JP2018503687A/ja active Pending
- 2016-01-20 US US15/001,853 patent/US9415008B2/en active Active
- 2016-01-20 HK HK18104726.3A patent/HK1245125A1/zh unknown
- 2016-01-20 WO PCT/US2016/014072 patent/WO2016118589A1/en not_active Ceased
- 2016-01-20 CN CN201680011413.7A patent/CN107530357A/zh active Pending
- 2016-01-20 US US15/544,900 patent/US20180015035A1/en not_active Abandoned
- 2016-01-20 KR KR1020177023075A patent/KR20170103975A/ko not_active Ceased
- 2016-01-20 AU AU2016209363A patent/AU2016209363B2/en active Active
- 2016-01-20 CA CA2974125A patent/CA2974125A1/en not_active Abandoned
- 2016-01-20 PE PE2017001234A patent/PE20171258A1/es unknown
- 2016-01-20 BR BR112017015353A patent/BR112017015353A2/pt not_active Application Discontinuation
- 2016-01-20 EA EA201791632A patent/EA201791632A1/ru unknown
- 2016-01-20 AR ARP160100136A patent/AR104771A1/es active IP Right Grant
-
2017
- 2017-07-12 MX MX2021006751A patent/MX2021006751A/es unknown
- 2017-07-16 IL IL253499A patent/IL253499A0/en unknown
- 2017-07-18 CL CL2017001859A patent/CL2017001859A1/es unknown
- 2017-08-17 CO CONC2017/0008395A patent/CO2017008395A2/es unknown
-
2021
- 2021-05-04 AU AU2021202784A patent/AU2021202784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1245125A1 (zh) | 2018-08-24 |
| US9415008B2 (en) | 2016-08-16 |
| KR20170103975A (ko) | 2017-09-13 |
| AU2016209363B2 (en) | 2021-02-04 |
| MX2017009122A (es) | 2017-10-12 |
| BR112017015353A2 (pt) | 2018-01-16 |
| US20160206559A1 (en) | 2016-07-21 |
| CA2974125A1 (en) | 2016-07-28 |
| PE20171258A1 (es) | 2017-08-28 |
| AR104771A1 (es) | 2017-08-16 |
| JP2018503687A (ja) | 2018-02-08 |
| WO2016118589A1 (en) | 2016-07-28 |
| EP3247331A1 (en) | 2017-11-29 |
| CN107530357A (zh) | 2018-01-02 |
| CL2017001859A1 (es) | 2018-04-06 |
| MX2021006751A (es) | 2021-07-15 |
| CO2017008395A2 (es) | 2018-01-05 |
| US20180015035A1 (en) | 2018-01-18 |
| AU2021202784A1 (en) | 2021-05-27 |
| MX383344B (es) | 2025-03-13 |
| IL253499A0 (en) | 2017-09-28 |
| MA41378A (fr) | 2017-11-28 |
| TW201628607A (zh) | 2016-08-16 |
| AU2016209363A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791632A1 (ru) | Ингалятор сухого порошка, содержащий флутиказон пропионат и сальметерол ксинафоат | |
| EA201690738A1 (ru) | Ингалятор сухого порошка | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| BR112018011266A2 (pt) | ?composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratar um paciente que sofre ou é propenso a sofrer de um distúrbio respiratório e para estabilizar uma composição farmacêutica? | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| EA201370162A1 (ru) | Новая фармацевтическая композиция со слабым побочным эффектом, включающая противотуберкулезные препараты | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2015015132A (es) | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. | |
| AU2018256668A1 (en) | Combination therapy comprising an inhibitor of JAK, CDK and PIM | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. | |
| PH12016500120A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| WO2016167605A3 (ko) | 고혈압 치료제를 이용한 흡연 및 비흡연자의 폐암 억제 방법 | |
| SA520420369B1 (ar) | تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| TH173838A (th) | เครื่องพ่นละอองยาผงแห้ง | |
| BR112019005133A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| BR112019005168A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica | |
| BR112019005080A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para aumentar o tempo de estabilização de uma composição farmacêutica, para melhorar o desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| UA105586U (uk) | Спосіб лікування печінкової енцефалопатії | |
| EA201991630A1 (ru) | Соединение хиназолина | |
| BR112019005120A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhorar o desempenho de dispersão em aerossol após armazenamento de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. | |
| UY35901A (es) | Nueva dosificación y formulación | |
| UA96221U (uk) | Спосіб лікування хворих на туберкульоз органів дихання |